| Document |
Document Title |
|
WO/2008/123821A1 |
The present invention relates to new compounds of formula (I), as a free base or salts thereof, to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy. The present invention further relates t...
|
|
WO/2008/124097A2 |
Disclosed herein are crystalline compounds of formula (I), wherein A+ represents y hydroxylated aliphatic ammonium species; and X and Y independently represent leaving groups.
|
|
WO/2008/120475A1 |
Disclosed is a method for producing an alcohol from a lactone or a carboxylic acid ester, which enables to produce an alcohol from a lactone or a carboxylic acid ester under relatively mild conditions with high yield and high catalytic e...
|
|
WO/2008/117704A1 |
3,3'-Diamino-5,5'-diphenyl-4,4'-biphenyldiol, which is useful as a monomer for high-performance polymers, especially ones satisfying a high degree of performance requirements in the field of semiconductors, such as polybenzoxazoles and p...
|
|
WO/2008/115141A1 |
The present invention relates to compounds of formula (I), (XI) or (CI), to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the pre...
|
|
WO/2008/110338A1 |
The invention relates to a crystalline anhydrous desvenlafaxine succinate of Form V.
|
|
WO/2008/111563A1 |
[PROBLEMS] To produce an optically active sulfoxide compound which is useful as an intermediate or a starting material for the synthesis of a physiologically active substance such as a pharmaceutical agent, at high optical purity. [MEANS...
|
|
WO/2008/112313A2 |
Provided are processes for the preparation of amorphous O- desmethylvenlafaxine and for the preparation of crystalline forms(I), (II), (III), and (IV) of O-desmethylvenlafaxine.
|
|
WO2008017278B1 |
A crystalline salt of 2-[(1R)-3-[bis(l-methylethyl)amino]-1-?henyl?ropyl]-4-methyl
-phenol with (2R,3R)-2,3-dihydroxybutanedioic acid, known under the name R-tolterodine tartarate, wherein: a) at least 90 % of all crystals are present in...
|
|
WO/2008/103461A2 |
Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (-)-O-desmethylvenlafaxine, includi...
|
|
WO/2008/099730A1 |
Disclosed is a novel optical resolving agent for an amine compound, which can be produced on an industrial scale in a simple manner and at low cost. An optically active 2-(aroyloxy)propionic acid can be used as an optical resolving agent...
|
|
WO/2008/095678A1 |
Optically active 2-amino-l-phenylethanols of formula (I) or its mirror image, wherein R1 is C1-6 alkyl or aryl-substituted C1-6 alkyl and R2 through R6 are independently hydrogen, hydroxy or C1-6 alkoxy, or salts thereof are prepared by ...
|
|
WO/2008/093142A1 |
The present invention relates to a novel process for the preparation of O-desmethyl 5 venlafaxine (ODV).
|
|
WO/2008/093686A1 |
Disclosed is a salt, particularly an ionic liquid, of a nonsteroidal anti-inflammatory drug (NSAID) comprising a carboxylic acid and an organic amine compound, which has properties required for a preparation for external application (e.g...
|
|
WO/2008/092327A1 |
Provided are half-hydrated crystal of voglibose and the preparation thereof. Said half-hydrated crystal has the molecular formula of C10H21NO7 0.5H2O and the powder X-ray diffraction pattern with peaks of 2θ=9.64±0.2, 16.08±0.2, 18.34...
|
|
WO/2008/090465A2 |
The invention relates to a process for manufacturing desvenlafaxine free base and salts or solvates thereof, comprising O-demethylating venlafaxine by treatment with 2- (diethylamino) ethanethiol free base or its hydrochloride salt.
|
|
WO/2008/088632A2 |
Biocidal compositions and their use in aqueous media, such as metalworking fluids, the compositions comprising a biocidal agent; and a non-biocidal primary amino alcohol compound of the formula (I); wherein R1, R2, R3, R4, and R5 are as ...
|
|
WO/2008/087493A1 |
The novel positively charged pro-drugs of retinoids and retinoid-like compounds in the general formula (31) 'Structure 31' were designed and synthesized. The compounds of the general formula (31) 'Structure 31' indicated above can be pre...
|
|
WO/2008/083708A1 |
The present invention relates to an improved process for the preparation of essentially pure Venlafaxine Hydrochloride. Particularly, the process for the preparation of Venlafaxine Hydrochloride comprises the following steps: i) Preparat...
|
|
WO/2008/077799A2 |
A method of making an amino-alkylenediol and intermediate compounds useful in the method is disclosed. The method includes preparing a first intermediate compound comprising an aminoalkylene diol wherein a protecting group is linked to t...
|
|
WO/2008/077769A1 |
An improved process for the safe ozonolysis of unsaturated, organic carbon compounds having one or more olefinic or aromatic double bonds in the molecule in flammable solvents for the preparation of mono- or biscarbonyl or hydroxy compou...
|
|
WO/2008/077560A1 |
Optically active 2-amino-l-phenylethanols of formula (I) or its mirror image, wherein R1 is hydrogen, C1-6alkyl or aryl-substituted C1-6alkyl and R2 through R6 are independently hydrogen, hydroxy or C1-6alkoxy, or salts thereof are prepa...
|
|
WO/2008/075516A1 |
A fluorinated diamine represented by the formula (1). In the formula, R1 represents a fused polycyclic aromatic hydrocarbon group, and at least one of the -C(CF3)2OH groups and at least one of the NH2 groups bond respectively to two adja...
|
|
WO/2008/072773A1 |
Disclosed is a production method comprising the steps (A)-(E) below, which enables to commercially and safely produce (1R,2R)-2-amino-1-cyclopentanol or a hydrochloride thereof.
|
|
WO/2008/070909A1 |
The present invention relates to a process for obtaining the R-enantiomer of salbutamol from a mixture of the enantiomers of salbutamol by a crystallization of said R-enantiomer as its salt with R-ibuprofen from a solution or slurry of a...
|
|
WO/2008/070496A2 |
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels...
|
|
WO/2008/068628A2 |
The invention relates to an asphaltene stabilisation and anti-coking additive containing condensed cresol alkyl amine, a surfactant and a hydrogen donor compound. Optionally, the additive contains condensed sulphonic alkylphenyl acids. P...
|
|
WO/2008/068927A1 |
Equipment for the production of amines which is constituted of a reactor (11) for conducting the reaction of a mono(lower alkyl)amine (raw material (I)) with an alkylene oxide (raw material (II)), a distillation column (14) for separatin...
|
|
WO/2008/064320A2 |
Hydrindane analogs of formula (IA) and (IB) that have agonist activity at one or more of the SlP receptors are provided. The ' compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
|
|
WO/2008/064315A1 |
Tetralin analogs that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
|
|
WO/2008/064337A2 |
Benzocycloheptyl analogs that have agonist activity at one or more of the S IP receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at SlP receptors.
|
|
WO/2008/058111A2 |
Provided are methods of preparing halohydroxypropyltrialkylammonium halides.
|
|
WO/2008/053652A1 |
A process for producing 1-hydroxy-4-aminoadamantane shown below. wherein R1 and R2 independently represent a hydrogen, a halogen, a carboxy, a nitro, an alkyl which may be substituted, an alkoxy which may be substituted, an alkylsulfonyl...
|
|
WO/2008/051558A2 |
The present invention provides novel isolated compounds characterized as metabolites or derivatives of desmethylvenlafaxine including hydroxy-DV metabolites, hydroxy-DV-glucuronide metabolites, N-oxide-DV metabolites, and benzyl-hydroxy-...
|
|
WO/2008/049317A1 |
Disclosed are biphenyl acetate, preparation and uses thereof. Said biphenyl acetate is biphenyl acetic ammonia butantriol salt, which is obtained by reacting biphenyl acetic acid with ammonia butantriol in organic solvent. Said salt can ...
|
|
WO/2008/047167A1 |
T h e present invention relates to crystalline forms of O-desmethyl venlafaxine ( O D V ) succinate monohydrate, namely Forms I and II, in pure form and to novel processes for their preparation. The present invention provides a process f...
|
|
WO/2008/048988A2 |
This invention relates to novel macromolecular compositions having oxidation inhibition characteristics that are exhibited when added to organic material normally susceptible to oxidative degradation in the presence of air or oxygen, suc...
|
|
WO/2008/048990A2 |
This invention relates to processes for the production of reaction mixtures, which have oxidation inhibition characteristics, using sterically hindered 4-alkoxymethyl-2,6-dihydrocarbylphenol and aromatic amines or heterocyclic compounds.
|
|
WO/2008/048989A2 |
This invention relates to novel macromolecular amine-phenolic compositions having oxidation inhibition characteristics that are exhibited when added to organic material normally susceptible to oxidative degradation in the presence of air...
|
|
WO/2008/047839A1 |
Disclosed is a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, which can act as a 5-HT1A receptor agonist (serotonin 1A agonist) and is useful as a therapeutic or prophylactic agent for a mood disor...
|
|
WO/2008/048987A1 |
This invention relates to processes for the production of reaction mixtures, which find use as antioxidants in a variety of applications, using sterically hindered 4-hydroxymethyl-2,6-dihydrocarbylphenol and aromatic amines or heterocycl...
|
|
WO/2008/041054A1 |
The novel positively charged pro-drugs of prostaglandins, prostacyclins and related compounds in the general formula (2) 'Structure 2' were designed and synthesized. The compounds of the general formula (2) 'Structure 2' indicated above ...
|
|
WO/2008/042362A1 |
The present invention is directed to arylamino-arylpropanolamine derivatives of formula I: I or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatm...
|
|
WO/2008/041059A1 |
The novel positively charged pro-drugs of mustards and related compounds in the general formula (1) 'Structure 1' were designed and synthesized. The compounds of the general formula (1) 'Structure 1' indicated above can be prepared from ...
|
|
WO/2008/038637A1 |
Disclosed is a clean, simple, and general-purpose method for producing a free amine from a salt of an amine having 1 to 10 carbon atoms which may have a substituent with an acid, which does not need to use water or any organic solvent, a...
|
|
WO/2008/035369A2 |
The present invention relates to novel crystalline polymorphic form of O-desmethyl venlafaxine which is designated as form A and process for the preparation of the same.
|
|
WO/2008/031894A1 |
This invention relates to the fluorinated dialkoxy-diimine metal complexes prepared by reacting MX4 (M is a metal of group 4 and X: halogen, alkyl or benzyl) with a ligand defined by the general formula: 1. A fluorinated dialcohol-diimin...
|
|
WO/2008/029200A1 |
The novel positively charged pro-drugs of acetaminophen, acetaminosalol, and related compounds in the general formula (1) 'Structure 1' were designed and synthesized. The positively charged amino groups of these pro-drugs not only largel...
|
|
WO/2008/027707A2 |
A method of making high diastereoselective and enantiomerically pure pseudonorophedrine and the hitherto unknown compound (1R,2R) pseudonorophedrine.
|
|
WO/2008/024634A1 |
A compound of formula (I) or a salt or solvate thereof: Formula (1) compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medicaments. Such mono-anilino pyr...
|
